One CEO says that last month's phony cancer drug scare should be a wake-up call for the industry.
While farmers liberally administer the drugs to their animals to prevent the spread of disease, all they are doing is opening the doors for stronger
Implantable medical devices in the supply chain haven't always received the attention they deserve from authorities.
Tthe FDA wants healthcare providers to rate current labeling based on its usefulness (particularly when it pertains to device instructions), coherence, organization and how often they are actually able to follow the instructions printed on the label.
Prescription drug manufacturers say they would be willing to provide physicians with more information on off-label uses, if the FDA would allow them.
With oversight managed by the Food and Drug Administration (FDA), the UDI database will, conceptually, increase label tracking and traceability in the medical device manufacturing industry by requiring product makers to record unique identifiers on each device's label.
Recently, the FDA released an updated compliance guide meant to provide pharmaceutical companies with the agency's latest position and thinking on the topic of PCIDs.
It's been little secret to professionals in the fishing industry that the standards for label compliance in their sector have been less than stellar. However, a recent investigative report by the Boston Globe publicized the dirty details.
In a recent press release, the Institute of Food Technologists (IFT) announced it would lead a pair of programs on behalf of the Food and Drug Administration (FDA) to determine better strategies for food label tracking and traceability.
by
sterling1
on
Oct 13, 2011 • Comments Closed
In a recent piece by Derek Singleton, who is the ERP Market Analyst at an online site called Software Advice, the writer makes his case that the cost of implementing a food traceability system …is going to force companies to invest a lot of money in infrastructure to meet FDA tracking and tracing standards. He’s...
by
sterling1
on
Oct 11, 2011 • Comments Closed
This post is about the long arm of the Food and Drug Administration (FDA) and the devastating impact that an FDA warning letter can have on a public company’s equity, even over labeling. It stems from a recent article in The Wall Street Journal by Sudeep Jain entitled “A Chance to Buy Aurobindo Pharma.” The crux of the...
An advocacy group of 300 companies, organizations and physicians has asked the Food and Drug Administration (FDA) to assert its regulatory power over genetically altered food, asking that these products be identified through labels.